Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Prism release

This article was originally published in The Gray Sheet

Executive Summary

Abbott's Prism automated blood supply testing platform was launched Oct. 13 following FDA approval of the HBcore assay, the system's first test menu option, for hepatitis core antigen. Additional hepatitis and HIV assays are currently under agency review. The Prism platform has been available outside of the U.S. for over 10 years, but the firm's 1999 consent decree delayed the approval of assay products produced at its Lake County, Ill. manufacturing facility (1"The Gray Sheet" May 20, 2002, p. 17). Units have already been shipped to 10 blood bank customers...

You may also be interested in...

Abbott’s Hep C Architect

Firm submits PMA application for an anti-hepatitis C virus test for use on the Architectanalyzer. It would be the first hepatitis assay approved for this platform in the U.S. Abbott markets a hepatitis C and two hepatitis A assays for its AxSYM platform, and the firm recently announced approval of its HBCore assay for its Prism automated blood supply testing system (1"The Gray Sheet" Oct. 31, 2005, In Brief)...

Abbott Prism Assays, Spectrum Of Product Launches Stalled By QSR Finding

Approval of Abbott Laboratories' Prism hepatitis B core antibody and HIV-1/2 assays likely will be delayed by FDA's finding that Abbott's Lake County, Illinois diagnostic manufacturing facility still does not comply with quality system regulations, the firm said

Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs

Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts